KPV is the C-terminal peptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH).

KPV has potent anti-inflammatory activity in the central nervous system, gastrointestinal tract, lungs, cardiovascular system, immune system, and joints. It has also been shown to be a promising treatment for inflammatory bowel disease (IBD).

As a short-chain peptide, KPV has high bioavailability and can be administered in multiple forms, including orally.

KPV for Inflammation and Healing

KPV has the potential to reduce intestinal inflammation and promote faster recovery from some intestinal disorders. KPV inhibits TNF-alpha and reduces the activity of mitogen-activated protein kinase and NF-kappaB (a protein complex that controls DNA transcription), helping to reduce inflammatory changes in the gut.

Studies show that KPV only acts against excessive inflammation and has little impact on non-inflamed tissue: KPV enters colon cells through PepT1, a protein channel that is only expressed in the intestine during inflammatory states.

Furthermore, KPV also acts as a general anti-inflammatory. This is because alpha-MSH and several of its analogues reduce inflammation associated with a wide variety of diseases, including dermatitis, vasculitis, fibrosis, and arthritis.

Similarly, KPV promotes wound healing and may reduce the type of chronic inflammation that leads to the formation of hypertrophic scars, such as keloids.